This editorial refers to 'Vessel wall, not platelet, P2Y 12 potentiates early atherogenesis' by L.E. West et al., this issue.
1
Platelet-triggered inflammatory pathways contribute to the formation of atherosclerotic lesions and atherothrombosis. Platelets express receptors for a variety of agonists that initiate platelet activation, which is then amplified and sustained by activation of the G-protein-coupled purinergic receptor P2Y 12 . P2Y 12 mediates platelet aggregation and secretion of platelet granule contents in response to ADP.
2 P2Y 12 is also a wellestablished target for anti-thrombotic drugs, such as the thienopyridine compounds ticlopidine, clopidogrel, and prasugrel or the direct, reversible antagonists ticagrelor, cangrelor, and elinogrel. 2 Clinical studies have
shown that in addition to preventing arterial thrombus formation in patients with coronary artery syndromes or after stent implantation, anti-thrombotic/anti-platelet therapy is also associated with systemic anti-inflammatory effects. 3 While these findings imply an important role for P2Y 12 The intriguing conclusion from these experiments is that vessel wall rather than platelet P2Y 12 contributes to early lesion development in these animals. An earlier study from the same laboratory identified a predominant role for platelet P2Y 12 in neointima formation in response to ferric chloride-induced arterial injury and thrombosis. 5 These findings emphasize the critical role of platelets (and other blood-borne cells) in modulating the vessel wall response to injury. However, these observations do not exclude a role for P2Y 12 in the vessel wall because P2Y 12 expression would likely be higher in vessel wall cells of atherosclerotic than in naive animals. In human vascular smooth muscle cells, P2Y 12 expression is transcriptionally regulated via NK-kB, a key regulator of pro-inflammatory signalling pathways. 6 Activation of the NF-kB signalling pathway in atherosclerosis-prone areas has been well documented. 7 Another recent study also evaluated the role of P2Y 12 in lesion progression in ApoE mice following 20 weeks of high-fat diet. 8 In addition, thrombin, the central regulator of coagulation, has been shown to enhance P2Y 12 transcription through activation of the NF-kB signalling pathway in human vascular smooth muscle cells in vitro. 6 Possible actions of smooth muscle P2Y 12 may include induction of pro-inflammatory cytokine production and Gai-mediated signalling. 6 The opinions expressed in this article are not necessarily those of the Editors of Cardiovascular Research or of the European Society of Cardiology.
An obvious limitation of the study of West et al. is that it provides no information on the cell types expressing P2Y 12 in the vessel wall. The signalling pathways downstream of platelet P2Y 12 have extensively been studied. 13 Activation of P2Y 12 inhibits adenylate cyclase activity and subsequently reduces cAMP-mediated signalling such as granule secretion and regulates PI3 kinase and Akt signalling. 13 Whether ligation of P2Y 12 triggers similar pathways in vessel wall cells, i.e. in smooth muscle or endothelial cells, remains speculative. Potential proinflammatory and atherogenic effects of P2Y 12 may involve signalling pathways known to be present in both platelets and smooth muscle cells; for example, coupling to surface toll-like receptors or secretion of growth factors. 14,15 Figure 1 summarizes the possible actions and transcriptional regulation of P2Y 12 in cells of the vessel wall. An unexpected observation in this study was the failure of the P2Y 12 inhibitors ticagrelor and clopidogrel to reduce lesion size at the early disease stage. 4 Earlier studies have reported an effective inhibition of ADP-induced vasoconstriction by ticagrelor and clopidogrel in isolated arteries. 12 Whether the unresponsiveness to these anti-platelet compounds was due to their limited bioavailability within the vessel wall and/or differences in platelet and vessel wall P2Y 12 sensitivity to inhibitors remains to be investigated. However, indirect evidence suggests systemic anti-inflammatory effects of P2Y 12 inhibitors, which may extend beyond inhibition of platelet functions. 3 Clearly, additional studies are 4 indicates that activation of vessel wall rather than platelet P2Y 12 contribute to the development of early atherosclerotic plaques. This may reflect a pro-inflammatory function of P2Y 12 in the vessel wall. ADP-triggered pro-inflammatory signalling pathways coupled with NF-kB-regulated pathways would lead to chronic inflammation, cell proliferation, and ultimately progression of atherosclerotic lesions. Intriguingly, clinically approved P2Y 12 antagonists, which effectively block platelet P2Y 12 failed to affect atherosclerotic lesion progression in ApoE-deficient mice fed a Western diet for 4 weeks. ADP, adenosine-diphosphate; GPCRs, G-protein-coupled receptors; Gi, Gq, G-proteins coupling to GPCRs; TLRs, toll-like receptors.
